Status and Outlook Analysis Report 2022

Overview Of The Development Of China's Pharmaceutical Industry

2021 China's pharmaceutical market size of 1,922 billion RMB, is expected to further reach 223.11 billion RMB in 2022 China's pharmaceutical market size.

In recent years, the scale of China's pharmaceutical market has been growing at a relatively fast pace.

 

2021 China's Pharmaceutical Market Boom Continues

From February to October 2021, the overall operating revenue and total profit of pharmaceutical manufacturing industry showed a trend of declining growth rate, with the year-on-year growth rate of revenue declining from 37.70% in February to 22.80% in October and the year-on-year growth rate of total profit declining from 95.40% in February to 76.70% in October. The main reason for this result is the low base of the epidemic factor in the first half of last year, and the lower comparable base effect disappeared month by month after the epidemic was brought under control in 2020.

ENTER

According to the financial reports of major Chinese CXO companies, Chinese CDMO companies, led by Hechuan Pharmaceuticals, have shown strong upward growth in the past three years, with an average compound growth rate of 28% in the number of projects of Chinese core CDMO companies. Meanwhile, revenue and net income of major Chinese CXO companies grew 41.8% and 49.4% year-over-year respectively. In the first three quarters of 2021, with strong performance growth also statically validating the high boom in drug development and outsourcing.

ENTER

The wave of products entering the global market is expected in 2022

China's innovative drugs is entering the global market

With the increase in the stock of innovative drugs year by year and the intensification of in-volume, coupled with the general background of medical insurance cost control, it has become a general trend for innovative drugs to enter the global market. However, in the context of the relative lack of funds for medical insurance, in order to protect more types of diseases and cover a wider range of patients, limiting the price of listed drugs through medical insurance negotiations has become an effective means of policy regulation.

ENTER

Driven by the COVID-19 epidemic, China's vaccine industry accumulates a large amount of cash under the domestic sales + export model of COVID-19 vaccine throughout 2021, laying a good financial foundation for future innovation and development on one hand, and laying a good foundation for other categories of vaccines to enter the global market in the future on the other hand. As of December 2021, the cumulative vaccination of China's COVID-19 vaccine exceeded 2.5 billion doses; in terms of export, from the customs data, China's human vaccine export continued to increase in 2021, and considering the repeated impact of the epidemic, there is still room for overseas export in the future.

ENTER

Biological research reagents mainly include molecular, protein and cellular reagents. Molecular reagents are mainly nucleic acid reagents, which are mainly used in nucleic acid-related experiments such as PCR amplification and DNA sequencing involving various tool enzymes, substrates, etc. In recent years, the development of new fields such as nucleic acid drugs, cellular gene therapy and PROTAC has given nucleic acid reagents new application scenarios. Protein reagents mainly refer to the types of reagents needed for experiments around protein macromolecules, including recombinant protein reagents and antibody reagents, etc. Cell-based reagents mainly refer to the reagents used in experiments around in vitro cells, including specific cells and products or kits for cell culture, transfection, apoptosis detection, lysis of cells, etc.

ENTER